Pyxis Oncology, Inc.
News
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average Target Price from Brokerages
Ticker Report Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned an average rating of "Buy" from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Eight...\n more…
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Globe Newswire BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...\n more…
Q3 2024 Earnings Estimate for Pyxis Oncology, Inc. (NASDAQ:PYXS) Issued By William Blair
Ticker Report Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities research analysts at William Blair upped their Q3 2024 earnings per share (EPS) estimates for Pyxis Oncology in a research note issued on...\n more…
Pyxis Oncology (NASDAQ:PYXS) Earns "Buy" Rating from HC Wainwright
Ticker Report Pyxis Oncology (NASDAQ:PYXS - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently...\n more…
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nPYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024.\nThe post PYXS...\n more…